EC
LXEO icon

EntryPoint Capital’s Lexeo Therapeutics LXEO Stock Holding History

EntryPoint Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482K Buy
103,648
+87,088
+526% +$471K 0.12% 335
2026
Q1 		$95.1K Buy
+16,560
New +$117K 0.03% 708
2024
Q3 		– Sell
-10,542
Closed -$169K – 1040
2024
Q2 		$169K Buy
+10,542
New +$153K 0.08% 497

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

EntryPoint Capital's LXEO Position: Q2 2026 in Review

EntryPoint Capital increased its Lexeo Therapeutics (LXEO) stake by 526% in Q2 2026, buying an estimated $471K and bringing the position to 103,648 shares worth $482K. The position accounts for 0.12% of the portfolio, ranked #335.

EntryPoint Capital first reported a position in LXEO in Q2 2024 and has held it in 3 quarters since. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • EntryPoint Capital held 103,648 shares of Lexeo Therapeutics worth $482K as of Q2 2026.
  • EntryPoint Capital bought 87,088 Lexeo Therapeutics shares in Q2 2026, an estimated $471K.
  • Lexeo Therapeutics made up 0.12% of EntryPoint Capital's portfolio in Q2 2026, its #335 holding.
  • EntryPoint Capital first reported a position in Lexeo Therapeutics in Q2 2024 and has held it in 3 quarters since.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.